Insights

Acquisition Opportunity 89bio was acquired by Roche in September 2025, signaling a strategic alignment under a major pharma group. This presents a sales window to engage Roche’s Pharmaceuticals Division about ongoing development of pegozafermin and potential cross-portfolio collaborations, licensing, or expanded access programs.

Clinical Momentum Pegozafermin is in Phase 3 for MASH and severe hypertriglyceridemia, highlighting a late-stage pipeline with near-term commercialization potential. Sales teams can target hepatology and cardiometabolic specialists, CROs, and payer discussions around value-based access and outcomes data.

Strategic Fit As part of Roche, 89bio’s FGF21 analog complements Roche’s focus on liver and metabolic diseases. There is an opportunity to align on joint signaling to investors, leverage Roche’s distribution networks, and co-develop companion diagnostics or biomarker strategies.

Financial Readiness With substantial funding (1.2B) and mid-range revenue, the company is financially positioned for ongoing development and potential commercial-scale manufacturing partnerships. This enables discussions around milestone-driven deals, financing options, and supply chain collaborations.

Market Positioning The company portfolio targets sizable markets in obesity, type 2 diabetes, and liver diseases. Sales prospects include multi-asset licensing, collaboration on additional indications, and partnerships with large biopharma to broaden the reach of pegozafermin and related metabolic therapies.

Similar companies to 89bio

89bio Tech Stack

89bio uses 8 technology products and services including Power BI, SAS, WordPress, and more. Explore 89bio's tech stack below.

Media & News

89bio's Email Address Formats

89bio uses at least 1 email format:
89bio Email FormatsExamplePercentage
First.Last@89bio.comJohn.Doe@89bio.com
100%

Frequently Asked Questions

What is 89bio's stock symbol?

Minus sign iconPlus sign icon
89bio is a publicly traded company; the company's stock symbol is ETNB.

What is 89bio's official website and social media links?

Minus sign iconPlus sign icon
89bio's official website is 89bio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does 89bio generate?

Minus sign iconPlus sign icon
As of October 2026, 89bio's annual revenue is estimated to be $25M - $50M.

What is 89bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
89bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does 89bio have currently?

Minus sign iconPlus sign icon
As of October 2026, 89bio has approximately 114 employees across 4 continents, including North America, Asia and Europe. Key team members include Chief Technical Operations Officer And Head Of Quality: Q. L., Vice President Cmc: S. J. and Vice President Regulatory Affairs: J. C. Explore 89bio's employee directory with LeadIQ.

What industry does 89bio belong to?

Minus sign iconPlus sign icon
89bio operates in the Biotechnology Research industry.

What technology does 89bio use?

Minus sign iconPlus sign icon
89bio's tech stack includes Power BI, SAS, WordPress, SAP, NetSuite, Shopify, Microsoft 365 and WP Engine.

What is 89bio's email format?

Minus sign iconPlus sign icon
89bio's email format typically follows the pattern of First.Last@89bio.com. Find more 89bio email formats with LeadIQ.

How much funding has 89bio raised to date?

Minus sign iconPlus sign icon
As of October 2026, 89bio has raised $1.2B in funding. The last funding round occurred on Feb 28, 2025 for $288M.

When was 89bio founded?

Minus sign iconPlus sign icon
89bio was founded in 2018.
89bio logo

89bio

Biotechnology ResearchCalifornia, United States51-200 Employees

89bio is a biotechnology research company headquartered in San Francisco, California, United States, employing 51-200 people. In September 2025, the company was acquired by Roche and became part of the Roche Group, integrated into Roche Pharmaceuticals Division. It develops pegozafermin, an FGF21 analogue, which is in Phase 3 trials for metabolic liver and cardiometabolic conditions, specifically Metabolic Dysfunction-Associated Steatohepatitis and severe hypertriglyceridemia. 89bio operates in the biotechnology research industry and maintains a corporate website at https://89bio.com. The company reports revenue in the range of $50 million to $100 million and has funding of $288 million.

Section iconCompany Overview

Website
89bio.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ETNB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
51-200

Section iconFunding & Financials

  • $1.2B

    89bio has raised a total of $1.2B of funding over 9 rounds. Their latest funding round was raised on Feb 28, 2025 in the amount of $288M as a Post IPO Equity.

  • $25M - $50M

    89bio's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.